A Study of SHR-1802 in Patients With Advanced Solid Tumor

Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Study ID
NCT05208177
Phase
PHASE2
Status
Terminated

Conditions

  • Advanced Solid Tumor

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

To assess the safety and tolerability of SHR-1802 combined with camrelizumab and famitinib in subjects with advanced solid tumor and to determine the dose-limiting toxicity (DLT)，recommended phase II dose (RP2D) and assess objective response rate (ORR) assessed by the investigator based on RECIST v1.1 criteria.

Key Dates

Start date
Apr 22, 2022
Status verified
Aug 2025
Primary completion
Aug 18, 2023
Completion
Aug 18, 2023

Study Design

Enrollment
25 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: SHR-1802 for injection combined with Camrelizumab for Injection and Famitinib Malate Capsules

Primary Outcome Measure

Dose limiting toxicity (DLT) [ Time Frame: 4 weeks ]

Related Studies